Ananda Plate – VJRegenMed

Myeloma Patients Europe: collaborating on projects to benefit the myeloma community

Marta Palhas — Fri, 26 Feb 2021 14:08:28 +0000

The Horizon 2020 CARAMBA project consortium investigates SLAMF7-CAR T-cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma. Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, discusses the role of Myeloma Patients Europe (MPE) in the CARAMBA project, which includes capturing patients’ needs, values, and experiences. Ms Plate outlines another project within the European Commission’s Horizon 2020 program that MPE are involved in – the MMPredict. Additionally, MPE participates in public-private partnerships such as the Innovative Medicines Initiative (IMI). This interview took place during the 3rd European CAR T-cell Meeting.

CAR T-cells in myeloma: patients’ perspective

Marta Palhas — Fri, 26 Feb 2021 14:08:27 +0000

CAR T-cell therapy has emerged as a promising therapy for relapsed and/or refractory patients with multiple myeloma. Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, discusses the challenges associated with this therapy from a patients’ perspective. The time lag between the collection and manufacturing of CAR T-cells remains difficult for patients with progressive disease. Side-effects, access to CAR T-cells, and management of expectations are some of the other hurdles related to CAR T-cell therapy. This interview took place during the 3rd European CAR T-cell Meeting.

The importance of partnering with patient organizations

Marta Palhas — Fri, 26 Feb 2021 14:08:27 +0000

Ananda Plate, LL.B, MSc, Myeloma Patients Europe, Brussels, Belgium, outlines the importance of partnering with patient organizations in research projects, focusing on Horizon 2020 projects such as CARAMBA. Patient organizations provide relevant patient and caregiver input to projects. In CARAMBA, Myeloma Patients Europe plays an important role in capturing and evaluating what patients and carers value, the patients’ experience while undergoing CAR-T therapy as well as patients’ expectations. This interview took place during the 3rd European CAR T-cell Meeting.